IMMUNOLIPOSOMAL ADRIAMYCIN AS AN ANTIVIRAL AGENT IN HIV INFECTED H9 CELLS

免疫脂质体阿霉素作为 HIV 感染 H9 细胞的抗病毒剂

• 批准号: 3792601
• 负责人: M P SELVAM
• 金额: --
• 依托单位: CENTER BIOLOGICS EVALUATION RESEARCH TRANSFUSION
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/3792601
• 关键词: HIV infections; antiviral agents; doxorubicin; drug screening /evaluation; human immunodeficiency virus; immunoconjugates; liposomes; tissue /cell culture

This project will evaluate the anti-HIV activity of adriamycin (doxorubicin), an anticancer drug which inhibits some viral reverse transcriptases (RT) in H9 cells infected with HIV-1 or HIV-2. HIV infects not only T cells but also cells of the mononuclear phagocytic system. We are developing a system in our laboratory to test antiviral drugs against HIV infected cells. Doxorubicin has been shown to be efficacious in the treatment of infectious Kaposi's sarcoma. Preliminary experiments demonstrate that treatment with 20-100 nanograms/ml of doxorubicin effectively inhibits HIV replication in H9 cells, but, at the same time, it is more toxic to the cells. To reduce the toxicity and make delivery of the drug to the target more specific, immunoliposomes are being prepared using HIV antigen-specific IgG conjugated to the liposome to specifically target infected cells.

本项目将评价阿霉素的抗HIV活性 （阿霉素），一种抗癌药物，抑制一些病毒逆转 在感染HIV-1或HIV-2的H9细胞中，艾滋病毒 不仅感染T细胞，还感染单核吞噬细胞 系统 我们正在实验室开发一个系统来测试抗病毒药物 抗HIV感染细胞的药物。阿霉素已被证明是 有效治疗传染性卡波西肉瘤。初步 实验表明，用20-100纳克/ml的 阿霉素有效地抑制HIV在H9细胞中的复制，但是， 同时，它对细胞的毒性更大。 为了减少毒性 并使药物更特异地递送到靶点， 使用HIV抗原特异性IgG制备免疫脂质体 与脂质体偶联以特异性靶向感染的细胞。